Status: Not yet recruiting
R-2487 in Patients With Sjogren's Syndrome (SS)
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Sjogren's Syndrome. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Rise Therapeutics LLCUpdated: Sep 4, 2025
Eligibility criteria
Diagnosis of SS according to American-European Consensus Group Criteria [+4]
No known active overlapping or associated other autoimmune disease [+11]